











Meet John

Regular Prospera testing helps minimize the risk of John's unique clinical factors leading to transplant rejection



<p>Clinical Factors that May Indicate Risk for Transplant Rejection</p>	 Donor-specific alloantibody (DSA) detected	 History of rejection	 Non-adherence to anti-rejection medication	 High Calculated Panel Reactive Antibody (cPRA)	 Delayed Graft Function (DGF) occurrence	 Decreased immune suppression due to infection and/or adverse effects	 Geographic distance or access to transplant center
<p>Factors Covered in Mary's Case Example</p>							



John's Patient Profile

AGE	37
RACE	Hispanic
LOCATION	Lansing, Michigan, close to a large transplant center
CLINICAL NOTES	<ul style="list-style-type: none"> Glomerulonephritis (GN) since early teens caused End-stage renal disease (ESRD) Received first transplant from mother (one haplotype match related donor) with good initial function Multiple rejections and recurrent GN caused graft loss after two years Received second transplant from a deceased donor in 2015 October 2016 - biopsy indicated antibody-mediated acute rejection (ABMR), with serum creatinine (sCr) of 1.8 mg/dL and positive for DSA. Treated with IVIG plasmapheresis and rituximab. June 2017 - biopsy showed tubulitis with tubular atrophy and indicated Banff 1A T-cell mediated rejection (TCMR). Treated with pulse steroids. February 2020 - developed cytomegalovirus (CMV) and DSAs remained detectable. His mycophenolate mofetil (MMF) was reduced from 1000 mg twice daily to 500mg twice daily.
RECENT VISIT	<ul style="list-style-type: none"> June 2020 - Prospera result was 1.7%. John's MMF was increased up to 1000mg twice daily. John's physician continued to monitor his Prospera levels. November 2020 - Prospera result decreased to 1.1%. Cr was 1.6 mg/dL January 2021 - Prospera was 0.9%. Cr was 2 mg/dL, which prompted a biopsy that showed moderate tubulointerstitial inflammation with no acute rejection as per Banff criteria. The biopsy resulted in no changes in clinical management.


Treatment Plan with Prospera



Monthly assessments with Prospera to determine if results are within range of previously established baseline.

Impact of Prospera Surveillance


John's physician used the Prospera result each month to assess if treatment was working.



Prospera result prompted the physician to **change immunosuppressant management** by increasing the MMF to 1000 mg twice per day.



Prospera results were **decreasing but the Cr was elevated** which was the impetus for the biopsy. The biopsy showed no active rejection.



Physician determined using **Prospera on a monthly basis could supplement Cr** results to reduce the need for biopsies prompted by elevated Cr alone.

KEY TAKEAWAY

Prospera surveillance testing allowed John's doctor to closely track fluctuations from the baseline result, which served as reassurance even though the Cr levels were rising. After a potentially unnecessary biopsy in January 2021, the physician determined future biopsies may be avoidable when Prospera results are available to supplement fluctuating Cr results due to Prospera's strong negative predictive value.¹



Prospera-powered monitoring for any transplant patient

Let's get started

Explore using Prospera for more frequently across a broader spectrum of patients through these options with Natera:



Request a clinical discussion between you and a local transplant nephrologist to hear why and how they have implemented surveillance monitoring with Prospera. Email prospera@natera.com to get connected.



Discuss potential surveillance options for your patient types with our clinical team to incorporate Prospera in your practice. Email prospera@natera.com to set up a clinical discussion.



Utilize the Natera physician portal to enable automatic scheduling of routine Prospera standing orders to certain patient cohorts. Reach out to your **Natera Sales Representative** for a demo.



View videos of other physicians and their stories about Prospera:
Visit us natera.com/prospera-for-any-type



Sigdel TK et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved.